Surfactant in airway disease

Area of Science:

• Pulmonary medicine
• Biochemistry
• Immunology

Background:

• Pulmonary surfactant is crucial for maintaining airway patency.
• Inflammation and invading plasma proteins can inhibit surfactant function.
• Asthma and respiratory infections are associated with impaired surfactant activity.

Purpose of the Study:

• To investigate the impact of plasma proteins and inflammation on pulmonary surfactant function.
• To explore the mechanisms behind surfactant dysfunction in asthma and respiratory infections.
• To evaluate the therapeutic potential of surfactant modulation in airway diseases.

Main Methods:

• Utilized pulsating bubble and capillary surfactometers to assess surfactant physical behavior.
• Studied calf lung surfactant extract inhibition by plasma proteins and temperature.
• Analyzed bronchoalveolar lavage fluid (BALF) from asthma patients and healthy volunteers.
• Investigated the role of eosinophil-synthesized enzymes in surfactant hydrolysis.

Main Results:

• Plasma proteins and lower temperatures inhibited surfactant function.
• Ozone inhalation and respiratory syncytial virus infection in mice led to surfactant malfunction due to airway protein invasion.
• BALF from allergen-challenged lungs of asthma patients showed poor surfactant performance, which improved after protein removal.
• Eosinophil enzymes (lysophospholipase and phospholipase A2) hydrolyze phosphatidylcholine, impairing surfactant.

Conclusions:

• Plasma protein invasion and enzymatic hydrolysis by eosinophils significantly impair pulmonary surfactant function in airway inflammation.
• Beta(2)-adrenergic agonists and steroids may improve asthma by promoting surfactant release.
• Nebulized surfactant administration presents a potential therapeutic strategy for airway diseases.